Drug General Information |
Drug ID |
D03STA
|
Former ID |
DCL000514
|
Drug Name |
Darotropium
|
Indication |
Chronic obstructive pulmonary disease [ICD9: 490-492, 494-496; ICD10:J40-J44, J47]
|
Discontinued in Phase 2 |
[1]
|
Company |
GSK
|
Structure |
|
Download
2D MOL
3D MOL
|
Target and Pathway |
Target(s) |
Muscarinic acetylcholine receptor M1 |
Target Info |
Agonist |
[2]
|
KEGG Pathway
|
Calcium signaling pathway
|
cAMP signaling pathway
|
Neuroactive ligand-receptor interaction
|
PI3K-Akt signaling pathway
|
Cholinergic synapse
|
Regulation of actin cytoskeleton
|
PANTHER Pathway
|
Alzheimer disease-amyloid secretase pathway
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
Muscarinic acetylcholine receptor 1 and 3 signaling pathway
|
Reactome
|
Muscarinic acetylcholine receptors
|
G alpha (q) signalling events
|
WikiPathways
|
Monoamine GPCRs
|
Calcium Regulation in the Cardiac Cell
|
Regulation of Actin Cytoskeleton
|
GPCRs, Class A Rhodopsin-like
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
Secretion of Hydrochloric Acid in Parietal Cells
|
GPCR ligand binding
|
GPCR downstream signaling
|
References |
REF 1 | Medicinal chemistry and therapeutic potential of muscarinic M3 antagonists. Med Res Rev. 2009 Nov;29(6):867-902. |
---|
REF 2 | Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). |